←Back to Expert Scholars
Translational Medicine / 转化医学Checkpoint Combinations, Early Phase Trials
Igor Puzanov
MD, MSCI
🏢Roswell Park Comprehensive Cancer Center🌐USA
Director, Early Phase Clinical Trials
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Igor Puzanov directs early-phase trials at Roswell Park and has led key studies of oncolytic virus combinations with checkpoint inhibitors including talimogene laherparepvec with pembrolizumab. He has advanced irAE management guidelines. His work explores novel immunotherapy combinations.
Share:
🧪Research Fields 研究领域
early phase trials
oncolytic virus combinations
talimogene laherparepvec
checkpoint combinations
melanoma
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Igor Puzanov 的研究动态
Follow Igor Puzanov's research updates
留下邮箱，当我们发布与 Igor Puzanov（Roswell Park Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment